Loading...

ONConcept® has successfully completed the pivotal BE study for Nilotinib

ONConcept January 2024

ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib. The study marks a significant milestone in our commitment to advancing pharmaceutical research and development in the field of Oncology.

The results demonstrate the efficacy of our formulation, covered by patent applications, and it allows us to file a dossier very soon with a potential launch in 2026.

This success reinforces our vision to providing timely and impactful solutions for patients globally, and it highlights ONConcept® commitment to improving patients’ health and positions us as a crucial provider for the future of oncology treatments.

Media
Bluepharma

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office

ONConcept April 2024

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office to maintain Medivation/Astellas formulation patent EP3725778 B1...

Bluepharma

ONConcept® has successfully completed the pivotal BE study for Nilotinib

ONConcept January 2024

ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib.The study marks a significant milestone in our commitment to...

Bluepharma

ONConcept® has successfully completed the pivotal BE study for Pomalidomide

ONConcept June 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

Bluepharma

Bluepharma opens an industrial unit unique in Portugal and one of the largest in Europe

ONConcept March 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

Bluepharma

How an Integrated European Hub for Complex Products is unlocking major market opportunities

Pharma Intelligence October 2022

The need for an integrated European developer and manufacturer of complex, differentiated and highly potent products is clearer than ever. Expirations on the patents and/or regulatory...

Bluepharma

ONConcept®: An Integrated European Hub for Delivering Highly Potent Complex Products

Pharma Intelligence July 2021

Off-patent, highly potent pharmaceuticals represent a major opportunity. The companies that seize the opportunity will grow sales by delivering products that improve the lives of patients...